|Year : 2015 | Volume
| Issue : 5 | Page : 164-165
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China
H Liu1, Y Wang2, N Liu3, L Zhao1
1 Department of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China
2 Department of Clinical Genetics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China
3 Department of Respiratory Medicine, Shenyang Chest Hospital, Shenyang, Liaoning, People's Republic of China
|Date of Submission||18-Oct-2013|
|Date of Acceptance||02-Jul-2014|
|Date of Web Publication||6-Feb-2015|
Department of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning
People's Republic of China
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Liu H, Wang Y, Liu N, Zhao L. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China. Indian J Med Microbiol 2015;33, Suppl S1:164-5
|How to cite this URL:|
Liu H, Wang Y, Liu N, Zhao L. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China. Indian J Med Microbiol [serial online] 2015 [cited 2020 Apr 1];33, Suppl S1:164-5. Available from: http://www.ijmm.org/text.asp?2015/33/5/164/150967
Tuberculosis (TB) has been a major health problem all over the world and China has the second highest prevalence of TB in the world. In China, multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains represents a serious public health concern.  These have led to demand for new anti-tuberculosis drugs. Linezolid, the first oxazolidinone antibiotics has been reported has the antituberculosis activity and may be used to treat MDR M. tuberculosis isolates. ,
We tested the in vitro activity of linezolid against 61 clinical strains of M. tuberculosis isolated from Shenyang Chest Hospital using the agar proportion method. Linezolid was provided by Pfizer (Zyvox ® ; Pfizer Inc., New York, NY, USA). The drug susceptibility test results of the 61 strains were 21 (34.4%) susceptible, 7 (11.5%) monoresistant to INH, 3 (4.9%) polyresistant to INH and OFL, 20 (32.8%) MDR-TB and 10 (16.4%) XDR-TB [Table 1]. The MICs of linezolid for the 61 strains are 0.125 - 1 μg/mL including 20 MDR-TB and 10 XDR-TB strains. This is lower than that of Prammananan et al. have reported.  And we did not find the strains which were resistance to linezolid. There were no differences in MIC 50 of linezolid among the groups, which were 0.25 μg/mL. Linezolid MIC 90 of XDR group was higher than that of the other groups, which were 0.5 μg/m and 0.25 μg/mL respectively [Table 1]
|Table 1: Resistance patterns of M. tuberculosis strains and in vitro activity of linezolid|
Click here to view
Our results suggest that linezolid has excellent activity against M. tuberculosis including MDR and XDR strains in China. Previously we have reported the clinical symptoms improved in three pulmonary TB patients (1 confirmed and 2 suspected) treating with linezolid . Because of the gastrointestinal and haematological adverse reactions of linezolid for long period used, we think that linezolid may be recommended for the treatment of XDR-TB with the other drugs in combination regimen with half of the routine doses.
| ~ References|| |
Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al
. Epidemiology of antituberculosis drug resistance 2002-07: An updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999;43:1189-91.
Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, et al
. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-5.
Prammananan T, Chaiprasert A, Leechawengwongs M. In vitro
activity of linezolid against multidrug resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int J Antimicrob Agents 2009;33:190-1.
Zhao L, Feng XW, Yan HY, Liu HB. Effects of linezolid in the treatment of patients with pulmonary tuberculosis. Chin J Clin Pharmacol 2009;25:60-3.